Details for Patent: 12,023,312

Which drugs does patent 12,023,312 protect, and when does it expire?

Patent 12,023,312 protects SOHONOS and is included in one NDA.

This patent has thirty-one patent family members in nineteen countries.

Summary for Patent: 12,023,312

Title:	Composition and method for muscle repair and regeneration
Abstract:	The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Inventor(s):	Masahiro Iwamoto, Maurizio Pacifici
Assignee:	Thomas Jefferson University
Application Number:	US17/881,207
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,023,312
Patent Claim Types: see list of patent claims	Use;

Recent additions to Drugs Protected by US Patent 12,023,312

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Ipsen	SOHONOS	palovarotene	CAPSULE	215559	Aug 16, 2023	RX	Yes	12,023,312					U-3966	REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA

Drugs Protected by US Patent 12,023,312

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-001	Aug 16, 2023		RX	Yes	No	12,023,312					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-002	Aug 16, 2023		RX	Yes	No	12,023,312					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-003	Aug 16, 2023		RX	Yes	No	12,023,312					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-004	Aug 16, 2023		RX	Yes	No	12,023,312					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-005	Aug 16, 2023		RX	Yes	Yes	12,023,312					REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA

International Family Members for US Patent 12,023,312

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011296080
Brazil	112013004685
Canada	2809374
Chile	2013000580
China	103200937
China	111773213